ArticleCellular oncology (Dordrecht, Netherlands)2026
ITGB5 promotes immune escape in hepatocellular carcinoma by regulating PD-L1 through SETDB1/Hippo signaling pathway.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe overall response rate to immune checkpoint inhibitors (ICIs) in HCC patients remains low. It has been reported that ITGB5 correlate with the immune infiltration of tumors. Our previous study showed that ITGB5 reduces HCC cell sensitivity to TKIs. However, the role of ITGB5 in HCC immunity remains unclear.
methodsThe mRNA and protein expression of ITGB5, SETDB1, LATS2 and PD-L1 in hepatocellular carcinoma cells and tissues were determined by RT-qPCR, Western Blot and Immunofluorescence. PD-L1 positive cells were analyzed by flow cytometry. The relationship between ITGB5 expression and immune cell infiltration was investigated by applying TIMER database. The effects of ITGB5 on the immune response and immunotherapy of hepatocellular carcinoma were determined by constructing a spontaneous tumor model of hepatocellular carcinoma and a subcutaneous tumor model in mice.
resultsITGB5 promotes immune escape in HCC by activating PD-L1 expression, a target gene of the Hippo signaling pathway, through the SETDB1-LATS2 axis. ITGB5 reduces the susceptibility of HCC to immunotherapy. Importantly, ITGB5 knockdown enhanced the efficacy of PD-1 therapy in mice harboring HCC.
conclusionsITGB5 plays an important role in the immune response of hepatocellular carcinoma. ITGB5 may serve as a biomarker for evaluating immunotherapy efficacy and represent a promising therapeutic target for HCC treatment, either alone or in combination with anti-PD-1 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.